Boswellic Acids: A Critical Appraisal of Their Therapeutic and Nutritional Benefits in Chronic Inflammatory Diseases.

Abstract

BACKGROUND:

In the last few decades, it has been largely perceived that the factors affecting the immune system and its varying pathways lead to the pathological progression of inflammation and inflammatory conditions. Chronic inflammation also contributes to common diseases, such as diabetes mellitus, ischemic heart disease, cancer, chronic renal inflammatory disease, non-alcoholic fatty hepatic disease, autoimmune diseases and neurodegenerative diseases.

OBJECTIVE:

Interestingly, plant sources and secondary metabolites from plants have been increasingly employed in managing acute and chronic inflammatory diseases for centuries. Boswellic acids are pentacyclic triterpenoidal moieties obtained from the oleo gum resin of different Boswellia species.

METHODS:

Detailed data was collected revealing the anti-inflammatory potential of Boswellic acids through various databases.

RESULT:

These are pharmacologically active agents that possess promising anti-inflammatory, anti-arthritic, antirheumatic, anti-diarrheal, anti-hyperlipidemic, anti-asthmatic, anti-cancer, and anti-microbial effects.

CONCLUSION:

Boswellic acids have been in use since ancient times primarily to treat acute and chronic inflammatory diseases. This review discusses the various mechanisms underlying the inflammatory process and the necessity of such natural products as a medication to treat inflammatory diseases. In addition, a discussion has also been extended to understand the primary targets involved in inflammation. The review further explores the therapeutic potential of boswellic acids in chronic inflammatory diseases by analyzing numerous reported scientific studies.

• Authors: Neeta Solanki, Gaurav Gupta, Dinesh Kumar Chellappan, Sachin Kumar Singh, Monica Gulati, Keshav Raj Paudel, Philip M Hansbro, Kamal Dua, Suraj Bhan, Manisha Saini, Harish Dureja
• Journal: Endocrine, metabolic & immune disorders drug targets (Endocr Metab Immune Disord Drug Targets) (May 12 2023) ISSN: 2212-3873 [Electronic] United Arab Emirates
• PMID: 37183464 (Publication Type: Journal Article)
• Copyright: Copyright© Bentham Science Publishers; For any queries, please email at [email protected].